Living Cell Technologies Limited (LVCLF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -1.57 Million AUD | -6.78% |
| 2023 | -1.47 Million AUD | 9.93% |
| 2022 | -2.36 Million AUD | -3.73% |
| 2021 | -1.33 Million AUD | 27.56% |
| 2020 | -3.14 Million AUD | 23.46% |
| 2019 | -4.11 Million AUD | 2.34% |
| 2018 | -4.2 Million AUD | 18.71% |
| 2017 | -5.17 Million AUD | -29.86% |
| 2016 | -3.98 Million AUD | 43.31% |
| 2015 | -7.03 Million AUD | -4.05% |
| 2014 | -6.75 Million AUD | -128.18% |
| 2013 | -2.96 Million AUD | -151.05% |
| 2012 | 5.8 Million AUD | 167.68% |
| 2011 | -8.57 Million AUD | -28.24% |
| 2010 | -6.68 Million AUD | 11.46% |
| 2009 | -7.55 Million AUD | -18.03% |
| 2008 | -6.39 Million AUD | -16.41% |
| 2007 | -5.49 Million AUD | 17.1% |
| 2006 | -6.62 Million AUD | -11.55% |
| 2005 | -5.94 Million AUD | -185.62% |
| 2004 | -2.08 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - AUD | -3.37% |
| 2024 Q2 | -574.41 Thousand AUD | 0.0% |
| 2024 Q3 | -215.18 Thousand AUD | 62.54% |
| 2024 Q4 | -215.18 Thousand AUD | 0.0% |
| 2024 Q1 | -574.41 Thousand AUD | -241.29% |
| 2023 Q1 | -465.16 Thousand AUD | 62.94% |
| 2023 Q3 | -168.25 Thousand AUD | 63.83% |
| 2023 Q4 | -168.3 Thousand AUD | -0.03% |
| 2023 Q2 | -465.16 Thousand AUD | 0.0% |
| 2023 FY | - AUD | 9.93% |
| 2022 Q1 | -301.7 Thousand AUD | 21.75% |
| 2022 FY | - AUD | -3.73% |
| 2022 Q2 | -1.12 Million AUD | -271.31% |
| 2022 Q4 | -1.25 Million AUD | -194.77% |
| 2022 Q3 | -425.77 Thousand AUD | 61.99% |
| 2021 FY | - AUD | 27.56% |
| 2021 Q2 | -279.55 Thousand AUD | 0.0% |
| 2021 Q1 | -279.55 Thousand AUD | 29.5% |
| 2021 Q3 | -382.54 Thousand AUD | -36.84% |
| 2021 Q4 | -385.56 Thousand AUD | -0.79% |
| 2020 FY | - AUD | 23.46% |
| 2020 Q3 | -387.68 Thousand AUD | 22.65% |
| 2020 Q2 | -501.22 Thousand AUD | 0.0% |
| 2020 Q4 | -396.54 Thousand AUD | -2.29% |
| 2020 Q1 | -501.22 Thousand AUD | 34.16% |
| 2019 FY | - AUD | 2.34% |
| 2019 Q1 | -489.72 Thousand AUD | 26.58% |
| 2019 Q4 | -761.29 Thousand AUD | -0.32% |
| 2019 Q2 | -489.72 Thousand AUD | 0.0% |
| 2019 Q3 | -758.85 Thousand AUD | -54.95% |
| 2018 Q1 | -643.47 Thousand AUD | -7.37% |
| 2018 FY | - AUD | 18.71% |
| 2018 Q4 | -667.05 Thousand AUD | -0.49% |
| 2018 Q3 | -663.78 Thousand AUD | -3.16% |
| 2018 Q2 | -643.47 Thousand AUD | 0.0% |
| 2017 Q3 | -605.71 Thousand AUD | 42.91% |
| 2017 FY | - AUD | -29.86% |
| 2017 Q4 | -599.31 Thousand AUD | 1.06% |
| 2017 Q1 | -1.06 Million AUD | -176.15% |
| 2017 Q2 | -1.06 Million AUD | 0.0% |
| 2016 Q2 | -814.56 Thousand AUD | 0.0% |
| 2016 FY | - AUD | 43.31% |
| 2016 Q4 | -384.2 Thousand AUD | 2.89% |
| 2016 Q3 | -395.62 Thousand AUD | 51.43% |
| 2016 Q1 | -814.56 Thousand AUD | 3.65% |
| 2015 Q4 | -845.46 Thousand AUD | -0.1% |
| 2015 FY | - AUD | -4.05% |
| 2015 Q2 | -680.21 Thousand AUD | 0.0% |
| 2015 Q3 | -844.63 Thousand AUD | -24.17% |
| 2015 Q1 | -680.21 Thousand AUD | -148.76% |
| 2014 Q3 | -273.65 Thousand AUD | 20.79% |
| 2014 Q2 | -345.48 Thousand AUD | 0.0% |
| 2014 Q1 | -345.48 Thousand AUD | -175.82% |
| 2014 FY | - AUD | -128.18% |
| 2014 Q4 | -273.43 Thousand AUD | 0.08% |
| 2013 Q3 | -98.57 Thousand AUD | 0.0% |
| 2013 FY | - AUD | -151.05% |
| 2013 Q4 | -125.26 Thousand AUD | -27.07% |
| 2012 FY | - AUD | 167.68% |
| 2011 FY | - AUD | -28.24% |
| 2010 FY | - AUD | 11.46% |
| 2009 FY | - AUD | -18.03% |
| 2008 FY | - AUD | -16.41% |
| 2007 FY | - AUD | 17.1% |
| 2006 FY | - AUD | -11.55% |
| 2005 FY | - AUD | -185.62% |
| 2004 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.37 Million USD | 90.908% |
| BioStem Technologies, Inc. | -7.55 Million USD | 79.094% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.679% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 97.146% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -68.547% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 90.049% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 59.344% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -149.713% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 399.413% |
| Qrons Inc. | -40.08 Thousand USD | -3840.026% |
| Skye Bioscience, Inc. | -13.54 Million USD | 88.343% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -330.041% |
| Rebus Holdings, Inc. | -951 Thousand USD | -66.057% |
| CSL Limited | 4.78 Billion USD | 100.033% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 9.76% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 97.777% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 73.364% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -560.34% |
| SQZ Biotechnologies Company | -64.14 Million USD | 97.538% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 40.282% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -2.809% |
| Mesoblast Limited | -62.38 Million USD | 97.469% |
| Marizyme, Inc. | -34.28 Million USD | 95.393% |
| Genus plc | 73.7 Million USD | 102.143% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 76.114% |
| Pharming Group N.V. | 9.87 Million USD | 115.989% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -6.171% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 55.478% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 81.997% |
| ContraFect Corporation | -64.99 Million USD | 97.57% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 65.11% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -12.655% |
| IMV Inc. | -35.52 Million USD | 95.554% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 32.043% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -204.838% |
| ONE Bio Corp. | 13.61 Million USD | 111.601% |
| Accustem Sciences Inc. | -3.74 Million USD | 57.848% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 96.725% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -24.628% |
| Q BioMed Inc. | -617.62 Thousand USD | -155.688% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 144.211% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 30.873% |
| Biomind Labs Inc. | -1.03 Million USD | -52.646% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 96.016% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 45.4% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 77.948% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 23586.05% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -6216.808% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 36.881% |
| GB Sciences, Inc. | -1.41 Million USD | -11.22% |
| Alpha Cognition Inc. | -9.7 Million USD | 83.729% |
| HST Global, Inc. | -5303.00 USD | -29679.408% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 23.228% |
| Halberd Corporation | -74.27 Thousand USD | -2026.041% |
| Enzolytics Inc. | -2.12 Million USD | 25.581% |
| Agentix Corp. | -1.37 Million USD | -15.123% |
| Resverlogix Corp. | -11.74 Million USD | 86.551% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 48.443% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 99.269% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 229.762% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 117.836% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -5.357% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 516.848% |
| AVAX Technologies, Inc. | -6.11 Million USD | 74.165% |
| Zenith Capital Corp. | -8.6 Million USD | 81.65% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.365% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -8964.933% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 35.45% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -797.15% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 17.789% |
| Kadimastem Ltd | -2.62 Million USD | 39.826% |
| Helix BioMedix, Inc. | -1.04 Million USD | -50.93% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -772.063% |
| LadRx Corporation | 412.28 Thousand USD | 483.038% |
| Cell Source, Inc. | -4.27 Million USD | 63.038% |
| Regen BioPharma, Inc. | 1.46 Million USD | 207.725% |
| NovAccess Global Inc. | -1.03 Million USD | -52.61% |
| Affymax, Inc. | -14.29 Million USD | 88.953% |
| Itoco Inc. | -1.86 Million USD | 15.505% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -315.995% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -41.506% |
| Mobile Lads Corp. | -2.24 Million USD | 29.536% |
| CytoDyn Inc. | -18.02 Million USD | 91.241% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1898.256% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -12813.582% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -225.154% |
| SYBLEU INC | -141.57 Thousand USD | -1015.484% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -48.699% |
| International Stem Cell Corporation | 202 Thousand USD | 881.783% |
| Bioxytran, Inc. | -3.82 Million USD | 58.661% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2900.004% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 35.855% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 95.597% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -3409.338% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 42.323% |
| Neutra Corp. | -181.24 Thousand USD | -771.298% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 92.166% |
| PureTech Health plc | -11.62 Million USD | 86.418% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 92.166% |
| IXICO plc | -707 Thousand USD | -123.367% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 79.451% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 96.734% |
| CSL Limited | 4.73 Billion USD | 100.033% |
| Cellectis S.A. | -92.63 Million USD | 98.295% |